☆ 4.7 Meeting Abstract

Phase II neoadjuvant trial of the anti-B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates

ANNALS OF ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S662-S663

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.08.1140

Keywords

-

Categories

Oncology

Funding

  1. Macrogenics
  2. Prostate Cancer Foundation
  3. American Society of Clinical Oncology Conquer Cancer Foundation
  4. Department of Defense

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.